Market Cap 154.23M
Revenue (ttm) 0.00
Net Income (ttm) -90.60M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,212,200
Avg Vol 2,145,042
Day's Range N/A - N/A
Shares Out 224.23M
Stochastic %K 41%
Beta 2.83
Analysts Strong Sell
Price Target $9.33

Company Profile

Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacet...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 825 6990
Address:
171 Oyster Point Boulevard, Suite 500, South San Francisco, United States
BIOVIC
BIOVIC Sep. 2 at 8:03 PM
$TNYA quiet tape today. tnya closed .70 up 2 percent on 1.2M vs 2.3M avg. tight 2 cent range, inside day doji. MMs holding it pinned. IR pushed random HDAC6 education content mid day. TN-301 has been silent for months. their programs page says it “would best be led by a strategic partner.” BD prep smell for JPM 2027 imo. new CFO hyllengren was hired to run capital markets. HFpEF is hot. HDAC6 differentiated. $75-125M upfront deal on a $148M mcap is huge non dilutive cash. column group still 27 percent. cash to Q3 2027. cohort 2 data Q4 2026. compliance clock ticks to jan 2027. sub .75 tape keeps me boring on the way in. no need to chase. #biovic nfa
0 · Reply
BIOVIC
BIOVIC Sep. 2 at 6:20 PM
$TNYA IR just pushed HDAC6 education content out of nowhere. TN-301 has been the forgotten stepchild of the pipeline for months while all the noise was TN-201 and TN-401. their own programs page literally says TN-301 “would best be led by a strategic partner with global resources.” that’s IR speak for we are shopping it. timing lines up with JPM 2027 in january. BD scouts monitor social sentiment before deals. new CFO hyllengren is a capital markets guy. HFpEF is red hot right now with lilly, novo, BI all fighting for differentiated mechanisms. HDAC6 is genuinely differentiated. a $75-125M upfront BD deal at zero dilution on a $148M market cap company is huge. non dilutive cash, partnership validation, and could help cure nasdaq compliance without needing an RS. watching if IR keeps drumming the HDAC6 story over next 4-6 weeks. if they present at any cardiovascular investor conference in oct nov thats confirmation. silence means it was just random content. nothing confirmed. just pattern recognition. #biovic nfa
1 · Reply
Vikenk187
Vikenk187 Sep. 2 at 5:10 PM
$TNYA any indications why it was up to .76 pre market
1 · Reply
Lsu189
Lsu189 Sep. 2 at 2:51 PM
0 · Reply
Rolfthewild
Rolfthewild Sep. 2 at 2:25 PM
0 · Reply
Minecraftbeers
Minecraftbeers Sep. 2 at 2:23 PM
$TNYA short interest went from ~25-26M shares (~12% float) most of july thru early aug, down to ~20-22M (~9-10% float) by mid-aug. that’s a real ~15-20% drop in shares short. lines up with the bounce off lows we saw mid-late aug. shorts were covering, which adds its own buying pressure. (Short interest is finra-reported biweekly/monthly with a lag, so “today’s” number is really the last official reporting date, not live.) still holding 9494 shares at $0.8571 average until Q4.
0 · Reply
7is7
7is7 Sep. 2 at 1:57 PM
$TNYA Bullish!
0 · Reply
Vikenk187
Vikenk187 Sep. 2 at 1:37 PM
0 · Reply
Minecraftbeers
Minecraftbeers Sep. 2 at 1:34 PM
0 · Reply
Damage111
Damage111 Sep. 1 at 9:55 PM
$TNYA come on 3 dollars 💵💵💵 😃
1 · Reply
Latest News on TNYA
Tenaya Therapeutics reports Q2 EPS (20c), consensus (7c)

2026-08-05T21:25:41.000Z - 4 weeks ago

Tenaya Therapeutics reports Q2 EPS (20c), consensus (7c)


Tenaya Therapeutics Quarterly report: Q2 2026

Aug 5, 2026, 4:00 PM EDT - 4 weeks ago

Tenaya Therapeutics Quarterly report: Q2 2026


Tenaya Therapeutics Earnings release: Q2 2026

Aug 5, 2026, 4:00 PM EDT - 4 weeks ago

Tenaya Therapeutics Earnings release: Q2 2026


Tenaya Therapeutics appoints Eric Hyllengren as CFO

2026-06-29T13:01:36.000Z - 2 months ago

Tenaya Therapeutics appoints Eric Hyllengren as CFO

ZURA


Tenaya Therapeutics Slides: FY 2026

Jun 4, 2026, 3:10 PM EDT - 3 months ago

Tenaya Therapeutics Slides: FY 2026


Tenaya Therapeutics management to meet with Piper Sandler

2026-06-03T20:45:27.000Z - 3 months ago

Tenaya Therapeutics management to meet with Piper Sandler


Tenaya Therapeutics Transcript: Study result

Jun 3, 2026, 8:00 AM EDT - 3 months ago

Tenaya Therapeutics Transcript: Study result


Tenaya Therapeutics Press release: Study result

Jun 3, 2026, 8:00 AM EDT - 3 months ago

Tenaya Therapeutics Press release: Study result


Tenaya Therapeutics Slides: Study result

Jun 3, 2026, 8:00 AM EDT - 3 months ago

Tenaya Therapeutics Slides: Study result


Tenaya Therapeutics Transcript: Study update

May 15, 2026, 10:30 AM EDT - 3 months ago

Tenaya Therapeutics Transcript: Study update


Tenaya Therapeutics Press release: Study update

May 15, 2026, 10:30 AM EDT - 3 months ago

Tenaya Therapeutics Press release: Study update


Tenaya Therapeutics Slides: Study update

May 15, 2026, 10:30 AM EDT - 3 months ago

Tenaya Therapeutics Slides: Study update


Tenaya Therapeutics reports Q1 EPS (9c), consensus (9c)

2026-05-07T00:34:31.000Z - 3 months ago

Tenaya Therapeutics reports Q1 EPS (9c), consensus (9c)


Tenaya Therapeutics Earnings release: Q1 2026

May 6, 2026, 4:00 PM EDT - 3 months ago

Tenaya Therapeutics Earnings release: Q1 2026


Tenaya Therapeutics Quarterly report: Q1 2026

May 6, 2026, 4:00 PM EDT - 3 months ago

Tenaya Therapeutics Quarterly report: Q1 2026


Tenaya Therapeutics Proxy statement: Proxy filing

Apr 16, 2026, 8:00 AM EDT - 4 months ago

Tenaya Therapeutics Proxy statement: Proxy filing


Tenaya Therapeutics Proxy statement: Proxy filing

Apr 16, 2026, 8:00 AM EDT - 4 months ago

Tenaya Therapeutics Proxy statement: Proxy filing


Tenaya Therapeutics reports Q4 EPS (12c), consensus (12c)

2026-03-11T20:27:09.000Z - 5 months ago

Tenaya Therapeutics reports Q4 EPS (12c), consensus (12c)


Tenaya Therapeutics Annual report: Q4 2025

Mar 11, 2026, 4:00 PM EDT - 5 months ago

Tenaya Therapeutics Annual report: Q4 2025


Tenaya Therapeutics Earnings release: Q4 2025

Mar 11, 2026, 4:00 PM EDT - 5 months ago

Tenaya Therapeutics Earnings release: Q4 2025


Tenaya Therapeutics presents preclinical data evaluating TN-301

2026-03-09T12:41:56.000Z - 5 months ago

Tenaya Therapeutics presents preclinical data evaluating TN-301


Tenaya Therapeutics announces 2026 strategic priorities

2026-01-09T13:41:19.000Z - 7 months ago

Tenaya Therapeutics announces 2026 strategic priorities


Tenaya Therapeutics 50M share Spot Secondary priced at $1.20

2025-12-12T07:00:10.000Z - 8 months ago

Tenaya Therapeutics 50M share Spot Secondary priced at $1.20


Tenaya Therapeutics Announces Pricing of Public Offering

Dec 12, 2025, 12:16 AM EST - 8 months ago

Tenaya Therapeutics Announces Pricing of Public Offering


Tenaya Therapeutics Transcript: Study Result

Dec 11, 2025, 5:00 PM EST - 8 months ago

Tenaya Therapeutics Transcript: Study Result


Tenaya Therapeutics Press release: Study Result

Dec 11, 2025, 5:00 PM EST - 8 months ago

Tenaya Therapeutics Press release: Study Result


Tenaya Therapeutics Slides: Study Result

Dec 11, 2025, 5:00 PM EST - 8 months ago

Tenaya Therapeutics Slides: Study Result


Tenaya Therapeutics  files to sell common stock, no amount given

2025-12-11T21:20:52.000Z - 8 months ago

Tenaya Therapeutics files to sell common stock, no amount given


Tenaya Therapeutics Announces Proposed Public Offering

Dec 11, 2025, 4:02 PM EST - 8 months ago

Tenaya Therapeutics Announces Proposed Public Offering


Tenaya Therapeutics Slides: Corporate Presentation

Dec 11, 2025, 7:00 AM EST - 8 months ago

Tenaya Therapeutics Slides: Corporate Presentation


Tenaya Therapeutics Transcript: Status Update

Nov 10, 2025, 8:00 AM EST - 9 months ago

Tenaya Therapeutics Transcript: Status Update


Tenaya Therapeutics Press release: Status Update

Nov 10, 2025, 8:00 AM EST - 9 months ago

Tenaya Therapeutics Press release: Status Update


Tenaya Therapeutics Slides: Status Update

Nov 10, 2025, 8:00 AM EST - 9 months ago

Tenaya Therapeutics Slides: Status Update


Tenaya Therapeutics Earnings release: Q3 2025

Nov 10, 2025, 7:00 AM EST - 9 months ago

Tenaya Therapeutics Earnings release: Q3 2025


Tenaya Therapeutics Quarterly report: Q3 2025

Nov 10, 2025, 7:00 AM EST - 9 months ago

Tenaya Therapeutics Quarterly report: Q3 2025


Tenaya Therapeutics Slides: Corporate Presentation

Sep 9, 2025, 7:00 AM EDT - 11 months ago

Tenaya Therapeutics Slides: Corporate Presentation


Tenaya Therapeutics Transcript: KOL Event

Aug 26, 2025, 11:30 AM EDT - 1 year ago

Tenaya Therapeutics Transcript: KOL Event


Tenaya Therapeutics Slides: Corporate Presentation

Aug 13, 2025, 4:00 PM EDT - 1 year ago

Tenaya Therapeutics Slides: Corporate Presentation


Tenaya Therapeutics Quarterly report: Q2 2025

Aug 6, 2025, 4:00 PM EDT - 1 year ago

Tenaya Therapeutics Quarterly report: Q2 2025


Tenaya Therapeutics Earnings release: Q2 2025

Aug 6, 2025, 4:00 PM EDT - 1 year ago

Tenaya Therapeutics Earnings release: Q2 2025


Tenaya Therapeutics Earnings release: Q1 2025

May 7, 2025, 4:00 PM EDT - 1 year ago

Tenaya Therapeutics Earnings release: Q1 2025


Tenaya Therapeutics Quarterly report: Q1 2025

May 7, 2025, 4:00 PM EDT - 1 year ago

Tenaya Therapeutics Quarterly report: Q1 2025


Tenaya Therapeutics Proxy statement: Proxy Filing

Apr 17, 2025, 8:00 AM EDT - 1 year ago

Tenaya Therapeutics Proxy statement: Proxy Filing


Tenaya Therapeutics Proxy statement: Proxy Filing

Apr 17, 2025, 8:00 AM EDT - 1 year ago

Tenaya Therapeutics Proxy statement: Proxy Filing


Tenaya Therapeutics Annual report: Q4 2024

Mar 10, 2025, 4:00 PM EDT - 1 year ago

Tenaya Therapeutics Annual report: Q4 2024


Tenaya Therapeutics Earnings release: Q4 2024

Mar 10, 2025, 4:00 PM EDT - 1 year ago

Tenaya Therapeutics Earnings release: Q4 2024


Tenaya Therapeutics Transcript: Study Update

Dec 17, 2024, 8:00 AM EST - 1 year ago

Tenaya Therapeutics Transcript: Study Update


Tenaya Therapeutics Press release: Study Update

Dec 17, 2024, 8:00 AM EST - 1 year ago

Tenaya Therapeutics Press release: Study Update


Tenaya Therapeutics Slides: Study Update

Dec 17, 2024, 8:00 AM EST - 1 year ago

Tenaya Therapeutics Slides: Study Update


Tenaya Therapeutics Quarterly report: Q3 2024

Nov 6, 2024, 4:00 PM EST - 1 year ago

Tenaya Therapeutics Quarterly report: Q3 2024


Tenaya Therapeutics Earnings release: Q3 2024

Nov 6, 2024, 4:00 PM EST - 1 year ago

Tenaya Therapeutics Earnings release: Q3 2024


Tenaya Therapeutics Quarterly report: Q2 2024

Aug 8, 2024, 4:00 PM EDT - 2 years ago

Tenaya Therapeutics Quarterly report: Q2 2024


Tenaya Therapeutics Earnings release: Q2 2024

Aug 8, 2024, 4:00 PM EDT - 2 years ago

Tenaya Therapeutics Earnings release: Q2 2024


Tenaya Therapeutics Announces Research Leadership Updates

Jun 27, 2024, 5:00 PM EDT - 2 years ago

Tenaya Therapeutics Announces Research Leadership Updates


Tenaya Therapeutics Quarterly report: Q1 2024

May 14, 2024, 4:00 PM EDT - 2 years ago

Tenaya Therapeutics Quarterly report: Q1 2024


Tenaya Therapeutics Earnings release: Q1 2024

May 14, 2024, 4:00 PM EDT - 2 years ago

Tenaya Therapeutics Earnings release: Q1 2024


Tenaya Therapeutics Proxy statement: Proxy Filing

Apr 17, 2024, 8:00 AM EDT - 2 years ago

Tenaya Therapeutics Proxy statement: Proxy Filing


Tenaya Therapeutics Proxy statement: Proxy Filing

Apr 17, 2024, 8:00 AM EDT - 2 years ago

Tenaya Therapeutics Proxy statement: Proxy Filing


Tenaya Therapeutics Earnings release: Q4 2023

Mar 18, 2024, 4:00 PM EDT - 2 years ago

Tenaya Therapeutics Earnings release: Q4 2023


Tenaya Therapeutics Annual report: Q4 2023

Mar 18, 2024, 4:00 PM EDT - 2 years ago

Tenaya Therapeutics Annual report: Q4 2023


BIOVIC
BIOVIC Sep. 2 at 8:03 PM
$TNYA quiet tape today. tnya closed .70 up 2 percent on 1.2M vs 2.3M avg. tight 2 cent range, inside day doji. MMs holding it pinned. IR pushed random HDAC6 education content mid day. TN-301 has been silent for months. their programs page says it “would best be led by a strategic partner.” BD prep smell for JPM 2027 imo. new CFO hyllengren was hired to run capital markets. HFpEF is hot. HDAC6 differentiated. $75-125M upfront deal on a $148M mcap is huge non dilutive cash. column group still 27 percent. cash to Q3 2027. cohort 2 data Q4 2026. compliance clock ticks to jan 2027. sub .75 tape keeps me boring on the way in. no need to chase. #biovic nfa
0 · Reply
BIOVIC
BIOVIC Sep. 2 at 6:20 PM
$TNYA IR just pushed HDAC6 education content out of nowhere. TN-301 has been the forgotten stepchild of the pipeline for months while all the noise was TN-201 and TN-401. their own programs page literally says TN-301 “would best be led by a strategic partner with global resources.” that’s IR speak for we are shopping it. timing lines up with JPM 2027 in january. BD scouts monitor social sentiment before deals. new CFO hyllengren is a capital markets guy. HFpEF is red hot right now with lilly, novo, BI all fighting for differentiated mechanisms. HDAC6 is genuinely differentiated. a $75-125M upfront BD deal at zero dilution on a $148M market cap company is huge. non dilutive cash, partnership validation, and could help cure nasdaq compliance without needing an RS. watching if IR keeps drumming the HDAC6 story over next 4-6 weeks. if they present at any cardiovascular investor conference in oct nov thats confirmation. silence means it was just random content. nothing confirmed. just pattern recognition. #biovic nfa
1 · Reply
Vikenk187
Vikenk187 Sep. 2 at 5:10 PM
$TNYA any indications why it was up to .76 pre market
1 · Reply
Lsu189
Lsu189 Sep. 2 at 2:51 PM
0 · Reply
Rolfthewild
Rolfthewild Sep. 2 at 2:25 PM
0 · Reply
Minecraftbeers
Minecraftbeers Sep. 2 at 2:23 PM
$TNYA short interest went from ~25-26M shares (~12% float) most of july thru early aug, down to ~20-22M (~9-10% float) by mid-aug. that’s a real ~15-20% drop in shares short. lines up with the bounce off lows we saw mid-late aug. shorts were covering, which adds its own buying pressure. (Short interest is finra-reported biweekly/monthly with a lag, so “today’s” number is really the last official reporting date, not live.) still holding 9494 shares at $0.8571 average until Q4.
0 · Reply
7is7
7is7 Sep. 2 at 1:57 PM
$TNYA Bullish!
0 · Reply
Vikenk187
Vikenk187 Sep. 2 at 1:37 PM
0 · Reply
Minecraftbeers
Minecraftbeers Sep. 2 at 1:34 PM
0 · Reply
Damage111
Damage111 Sep. 1 at 9:55 PM
$TNYA come on 3 dollars 💵💵💵 😃
1 · Reply
BIOVIC
BIOVIC Sep. 1 at 8:05 PM
$TNYA closed .6858 down .91% on 951k vol which is only 40% of average. vwap .6899, day range .6821 to .70. day one after nasdaq compliance move basically no volume no urgency either way. what happened intraday. opened .6972 held the .69-.70 range through 11am. midday sellers took it to .6821 low then afternoon buyers stepped back in and dragged it to .69 before it fell back into the close. moc push weak. no institutional print no distribution but no accumulation either. drift day. sector context. xbi +0.44 ibb +0.85 both green. spy -0.69 broad tape weak. tnya underperformed a green biotech tape by 130 bps. lxeo -1.26 to 4.70 still leaking. so the sector isnt the problem. this is name-specific consolidation. the tape story. we now have five straight sessions building base between .67 and .70. every walk down absorbed. every rip to .70 rejected. this is exactly what accumulation into a catalyst window looks like when mms are moving inventory quietly. column group still holds 23%, millennium 5.2% from august, insider ownership tight. why im not worried. tenaya guided next tn-401 ridge-1 data q4 2026 on aug 5 earnings call. that means anywhere from oct through december. we are five to ten weeks from ring 2 catalyst traders showing up. base building now is not weakness its patience. i added 36,603 today at .70 to round the position to 1m even shares. avg .9332. holding to the other side of nasdaq compliance and through aha week. for anyone new to the story. piper sandler still has $40 pt overweight (yasmeen rahimi) never wavered. chardan $8 canaccord $5 wainwright $3 so consensus $5.33. cash runway extends into 2027. tn-401 tn-201 tn-101 tn-301 all still active. this is a fully loaded biotech at .69 with 224m shares out. HODL. nfa #biovic
1 · Reply
g04168
g04168 Sep. 1 at 6:56 PM
$TNYA It's time .....
0 · Reply
Rolfthewild
Rolfthewild Sep. 1 at 3:42 PM
0 · Reply
Minecraftbeers
Minecraftbeers Sep. 1 at 2:52 PM
$TNYA even with that drop to 66 in the middle of the night we’re still back to 68-70 range which is good. We should stay here until we get ANY news in Q4. 68-70 is our floor
0 · Reply
BIOVIC
BIOVIC Sep. 1 at 1:36 PM
$TNYA just crossed 1,000,000 shares tnya. added 36,603 today at .70 to round it out. avg cost .9332, roughly $933K deployed. 25% underwater and not flinching. why the round number matters. this is the position size where you stop trading and start owning. 1m shares is .446% of shares outstanding which puts me in a different bucket than a swing trader. im long the science, long the founders, long the runway story getting resolved by q4. if any one of tn-201 tn-401 tn-101 tn-301 works, this position pays for itself many times over. if the whole platform works, piper’s $40 pt starts looking conservative. catalyst window still open. aha nov 6 to 9 with srivastava opening re.cvs.03 friday morning on cardiac reprogramming, byrne on mypeak-1 saturday morning, adler on the pkp2 pipeline same slot. three days three angles. before that, q3 earnings and cash runway update. srivastava on the board and chairing the sab. column group 23% and just added 35m shares at .70 in march. millennium crossed 5% in august. the institutional stack is quietly building. the tape has been building a base .67 to .70 for four straight days. every walk down absorbed. mm supply thinning. this isnt distribution, this is accumulation into a catalyst window with a runway story that gets resolved either way. im holding this to the other side of nasdaq compliance and through the aha week catalyst stack. if it works im not selling early. if it breaks the thesis fires and i exit. no middle ground. HODL. nfa #biovic
4 · Reply
MoonkidSamwise
MoonkidSamwise Sep. 1 at 7:25 AM
$TNYA Yasmeen Rahimi is the analyst. Her broader track record is actually quite strong. TipRanks currently ranks Rahimi #137 out of 12,499 Wall Street analysts. She estimates well example Nektar Therapeutics, which I did own. Piper's thesis isn't simply "TN-201 succeeds." Their July commentary specifically argued that the market was assigning essentially no value to TN-301, Tenaya's HDAC6 inhibitor, while Piper sees TN-301 as potentially important across several cardiovascular/orphan indications. However 40 bucks is quite wild.
1 · Reply
Ray89c
Ray89c Aug. 31 at 8:55 PM
$TNYA what’s is that we don’t know ? Piper Sandler maintains an Overweight (Buy) rating on Tenaya Therapeutics Inc (NASDAQ:TNYA) with a price target of $40.00, supported by ongoing clinical pipeline progress.
3 · Reply
Damage111
Damage111 Aug. 31 at 8:48 PM
$TNYA if there’s a lower dip than today I will be purchasing more 😎 holding till Q4 and hoping for the moon!!
1 · Reply
Paulfrench
Paulfrench Aug. 31 at 8:39 PM
$TNYA It’s been a while since we’ve seen a candle that brings a positive note; indeed, today’s candle forms a VSA divergence, signaling a reaction from buyers who are absorbing the bearish pressure and regaining control... in short, it’s great 😅... Not necessarily the signal yet that it’s about to take off, but things are shaping up.
2 · Reply
BIOVIC
BIOVIC Aug. 31 at 8:02 PM
$TNYA last .6878 down .33% on 1.63M shares vs 2.44M avg. day range .6741 to .6965. vwap .6854. mm walked it down midday to .6741 15:15 flush of 630k, tape absorbed it fast, closed the session at .6921 with the 19:50 bar popping to .6965 on 82k. that late lift is the tell. structure. higher low sequence intact for the fourth day. sunday .6555 flush, aug 28 low .6869, today low .6741. base building above the panic wick. mms getting no follow through on the walk downs. sector context. xbi +.06, ibb +.05, spy -.31. broad tape mildly red, biotech flat, tnya essentially flat with a strong close. no sector alpha to explain the tape either way. this is company specific accumulation grinding through mm supply. competitor tell. lxeo -2.06% to 4.76 on light volume. the pkp2 competitor keeps bleeding. thats useful because the two names typically move on aha week narrative correlation, but the divergence today (lxeo down more, tnya flat with strong close) says the tape isnt lumping them together anymore. good for us. catalyst window still 66 days out. aha nov 6 to 9 with three angles now on the board. srivastava opens re.cvs.03 friday morning 11:30 am ct on cardiac reprogramming (tn-101 platform territory). byrne on http://ge.me.06 saturday morning (tn-201 mypeak-1 lessons). adler pipeline session same slot (tn-401 competitive positioning vs lx2020). three days three angles. not adding, not trimming. HODL. base building at .68 to .70 is exactly where you want it heading into a catalyst window with cash runway pressure resolved by early q4 raise if needed. mm supply thinning and every walk down is getting absorbed. nfa #biovic
2 · Reply
7is7
7is7 Aug. 31 at 6:44 PM
$TNYA 7777 shares at $.84 hehe.
0 · Reply
Damage111
Damage111 Aug. 31 at 6:30 PM
$TNYA just bought another 2200 shares averaging down to .80 😀
0 · Reply